NANODRUGS

VolverGo back

Resultados 130 results. LastUpdate Updated on 30/09/2022 [11:42:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 15 días / Applications published in the last 15 days



previousPage Page2/6 nextPage   results/page


PD-L1 AND TLR7 DOUBLE-TARGETING NANOBODY COUPLING DRUG AND USE THEREOF IN ANTI-TUMOR

Publication No.: WO2022194153A1 22/09/2022

Applicant:

SHANGHAI INST MATERIA MEDICA CAS [CN]

CN_115068625_A

Absstract of: WO2022194153A1

Disclosed in the present invention are a use of a combination of an anti-PD-L1 nanobody and a TLR7 small molecule agonist in anti-tumor treatment, and a PD-L1 and TLR7 double-targeting nanobody coupling drug, a preparation method therefor, and a use thereof. Specifically, disclosed in the present invention are a use and solution of a combination of an anti-PD-L1 nanobody and a derived protein thereof as well as a TLR7 small molecule agonist and a derived compound thereof in anti-tumor treatment. Meanwhile, disclosed in the present invention are design, preparation, and identification solutions for a novel PD-L1 and TLR7 double-targeting nanobody drug conjugate and a derived molecule thereof, and an effect of the novel PD-L1 and TLR7 double-targeting nanobody drug conjugate in anti-tumor treatment. The PD-L1 and TLR7 double-targeting nanobody drug conjugate of the present invention can yield a significant antineoplastic efficacy in various transplantation tumor models.

traducir

EXTRACELLULAR VESICLE-BASED NANOCARRIERS

Publication No.: WO2022198187A1 22/09/2022

Applicant:

OHIO STATE INNOVATION FOUNDATION [US]

Absstract of: WO2022198187A1

Disclosed herein is a system that engages skin-resident APCs by directly delivering a vaccine composition, and a system that turns skin cells into a vaccine dispatch center to amplify immunity via the production of engineered extracellular vesicles (EVs) functionalized with targeting ligands and loaded with the vaccine composition that can be targeted to extracutaneous APCs. In particular, disclosed herein is a vaccine composition that involves a first polynucleotide encoding or comprising a viral, bacterial, or tumor antigen, and a second polynucleotide encoding a fusion protein comprising an APC-targeting ligand and an exosomal or lysosomal transmembrane protein. Also disclosed is a method of vaccinating a subject that involves transfecting skin cells of the subject with the disclosed vaccine composition. Also disclosed herein is a method of vaccinating a subject that involves administering to the subject the disclosed EV vaccine.

traducir

POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF

Publication No.: WO2022198099A1 22/09/2022

Applicant:

RECODE THERAPEUTICS INC [US]

Absstract of: WO2022198099A1

Compositions of polynucleotide(s) are disclosed. A polynucleotide may encode for a polypeptide, protein, or functional fragment thereof associated with primary ciliary dyskinesia (PCD). Pharmaceutical compositions, kits, and methods for treating a disease or condition associated with cilia maintenance and function, and impaired function of the axoneme are also disclosed. The polynucleotide may be combined with a lipid composition.

traducir

Dendrimer delivery system and methods of use thereof

Publication No.: AU2022221454A1 22/09/2022

Applicant:

UNIV JOHNS HOPKINS [US]

JP_2021502451_A

Absstract of: AU2022221454A1

DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. -120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.

traducir

Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof

Publication No.: AU2021231160A1 22/09/2022

Applicant:

PROGENEER INC

WO_2021177679_A1

Absstract of: AU2021231160A1

The present invention relates to: a lyophilized preparation of a pathogen cell wall skeleton, the preparation containing the pathogen cell wall skeleton as an active ingredient; various live-pathogen-mimetic nanoparticles produced by using the lyophilized preparation and antagonists of toll-like receptor 7 or 8 which can induce the efficacy of the live pathogen; a use thereof; and a production method thereof.

traducir

Methods and compositions using synthetic nanocarriers comprising immunosuppressant

Publication No.: AU2021225955A1 22/09/2022

Applicant:

SELECTA BIOSCIENCES INC

US_2021290601_A1

Absstract of: AU2021225955A1

Provided herein are methods and compositions related to synthetic nanocarriers comprising an immunosuppressant that can be used, for example, for inducing autophagy and/or promoting a tolerogenic phenotype.

traducir

Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells

Publication No.: AU2021218409A1 22/09/2022

Applicant:

GENEVANT SCIENCES GMBH

WO_2021163339_A1

Absstract of: AU2021218409A1

Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.

traducir

Methods of preparing lipid nanoparticles

Publication No.: AU2021212262A1 22/09/2022

Applicant:

MODERNATX INC

TW_202139976_A

Absstract of: AU2021212262A1

The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof. The present disclosure also provides therapeutic and diagnostic uses related to the produced LNP formulations.

traducir

METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS

Publication No.: US2022296543A1 22/09/2022

Applicant:

HADASIT MEDICAL RES SERVICES & DEVELOPMENT LIMITED [IL]
YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD [IL]

WO_2021028919_A1

Absstract of: US2022296543A1

Provided are methods for inhibiting binding of systemically administered drugs to a target in the skin by topically administering materials prior to or concomitantly with administration of the systemic drugs.

traducir

LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF

Publication No.: WO2022198229A1 22/09/2022

Applicant:

UNIV NEBRASKA [US]

Absstract of: WO2022198229A1

Disclosed herein are methods and compositions for lipid nanoparticles encapsulating a nucleic acid encoding for a CRISPR nucleic acid complementary to a HIV-1 gene. Also disclosed are lipid nanoparticle compositions, nucleotides, cells, and methods associated with the compositions.

traducir

LIPID-BASED NANOPARTICLE DELIVERY SYSTEM FOR HYDROPHILIC CHARGED COMPOUND

Publication No.: WO2022197988A1 22/09/2022

Applicant:

UNIV NAT TAIWAN

WO_2022197989_PA

Absstract of: WO2022197988A1

A lipid-based nanoparticle (LNP) with high DL ratio and normalized release. The LNP of the present invention comprises an outer lipid monolayer encapsulating a plurality of lipid-active pharmaceutical ingredient (API) complexes, wherein each lipid- API complex comprises a complex of anionic lipid and API wherein the API comprises a positively charged form of an API and wherein the outer lipid monolayer of the LNP comprises neutral lipids. The present invention further comprises a method of preparation of the LNP of the present invention.

traducir

COMPOSITION AND METHOD OF PREPARATION FOR LIPID FORMULATIONS COMPRISING CHARGED LIPIDS

Publication No.: WO2022197989A1 22/09/2022

Applicant:

FORMURX PHARMACEUTICALS CO LTD

WO_2022197988_PA

Absstract of: WO2022197989A1

A lipid-based nanoparticle (LNP) with high DL ratio and normalized release. The LNP of the present invention comprises an outer lipid monolayer encapsulating a plurality of lipid-active pharmaceutical ingredient (API)-ion complexes, wherein each lipid- API-ion complex comprises a complex of anionic lipid, API and ion wherein the API comprises a positively charged form of an API and wherein the outer lipid monolayer of the LNP comprises neutral lipids. The present invention further comprises a method of preparation of the LNP of the present invention.

traducir

DENDRITIC PEPTIDE CONJUGATED POLYMERS FOR EFFICIENT INTRACELLULAR DELIVERY OF NUCLEIC ACIDS TO IMMUNE CELLS

Publication No.: WO2022197977A1 22/09/2022

Applicant:

UNIV NORTHWESTERN [US]

Absstract of: WO2022197977A1

The present invention provides nanocarriers for delivering polynucleotide sequences to cells, specifically immune cells, including dendritic cells and methods of use. The methods provide improved delivery and reduced toxicity over prior methods. The method of the present disclosure provide a system for delivering nucleic acids to a cell, consisting of a synthetic PEG-b-PPS-linker-DP polymer for producing nanostructures comprising a poly(ethylene glycol)-blockpoly(propylene sulfide) copolymer (PEG-b-PPS) conjugated with a dendritic-specific branched cationic peptide (DP). The system provides a non-toxic in-vitro method of delivering a polynucleotide to immune cells, including dendritic cells, comprising of contacting the cell in cell culture medium with a nanocarrier wherein the method is non-toxic to the cells. The methods described in the invention can be used for treating a subject in need of gene therapy, comprising administering to the subject an effective amount of the system comprising of a polynucleotide, wherein the polynucleotide contains a gen of interest for gene therapy.

traducir

A METHOD FOR OBTAINING ION-EXCHANGE POLYMERIC HYDROGELS FOR EYE TREATMENT AND HYDROGEL LENSES THEREOF

Publication No.: US2022296506A1 22/09/2022

Applicant:

SIA MEDHYDROGEL [LV]

Absstract of: US2022296506A1

The present invention could be used in medicine and relates to a method of producing ion-exchange polymeric hydrogels for eye treatment, which includes monomer copolymerization under ionizing radiation in presence of linking agent and ionites, when copolymerization is carried out gradually to obtain a prepolymer of desired viscosity for filling lens forms, and ionites introduction in the form of finely dispersed powder, filing the hydrogel into lens forms and subsequent copolymerization till an adequate ionizing dosage is performed providing a gel suitable for lenses formation, characterized in that the gel is also filled with pharmaceutically active agent in the form of finely dispersed powder prior to ionite introduction, and the size of particles of PAA is lower that the size of ionite particles. The present invention also relates to therapeutic hydrogel lenses produced in accordance with the above-mentioned method.

traducir

FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING A2AR ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF

Publication No.: WO2022197344A1 22/09/2022

Applicant:

NAMMI THERAPEUTICS INC [US]

Absstract of: WO2022197344A1

Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising AR Prodrugs and methods of making the nanocarriers are disclosed herein. The AR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit A2aR. The AR Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

traducir

APPARATUS AND PROCESS FOR PRODUCING NANOCARRIERS AND/OR NANOFORMULATIONS

Publication No.: WO2022194615A1 22/09/2022

Applicant:

EVONIK OPERATIONS GMBH [DE]

EP_4059491_PA

Absstract of: WO2022194615A1

The invention relates to an apparatus (0) and process for producing nanocarriers and/or nanoformulations and corresponding process products. The present invention has for its object to specify an alternative process for producing nanocarriers/nanoformulations and an accompanying apparatus for performing this process. The apparatus (0) according to the invention is characterized by a vertical orientation of the feed conduits (4,5) leading to an active element (3). The feed conduits (4), (5) are nested within one another and axially movable in terms of their orientation to one another. The process according to the invention provides for the mixing of at least two liquid phases with different acidities. The volume flow of the first phase is greater than that of the second phase.

traducir

NANOEMULSION OF 18BETA-GLYCYRRHETINIC ACID

Publication No.: US2022296544A1 22/09/2022

Applicant:

ATSO CORP AFFAIRS S A DE C V [MX]

BR_112022002176_A2

Absstract of: US2022296544A1

The invention refers to pharmaceutical forms that potentiate the bioavailability of 18β-GA, having a high permeation on the application area mainly due to the effect of their small particle size, high concentration of the active ingredient, excipient composition, micelles with specific structural composition and polarity. The present pharmaceutical forms exhibit specific values for particle size, permeability, diffusion coefficient, and polydispersity helping to provide its technical advantages. Therapeutic uses of the pharmaceutical forms are also described, which include those therapeutic uses for which 18β-glycyrrhetinic acid is known to have an effect, such as anti-inflammatory, antiviral, antibacterial activity, hepatoprotective, used against skin diseases and anticarcinogenic. Mainly gelled solutions, emulsions and nanoemulsions, are intended for application in the vaginal and cervical area, for the treatment of diseases related to the human papillomavirus, such as infections, lesions, and cervical cancer.

traducir

PHARMACEUTICAL COMPOSITIONS

Publication No.: US2022296575A1 22/09/2022

Applicant:

XSPRAY PHARMA AB [SE]

US_2022168285_A1

Absstract of: US2022296575A1

The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

traducir

Small Molecule Agents, Compositions, and Formulations, for Internal Use, Displaying Inhibitory Activity Against Gram-positive and/or Gram-negative Organisms

Publication No.: US2022296549A1 22/09/2022

Applicant:

NATUREZA INC [US]

CA_3072197_A1

Absstract of: US2022296549A1

Active components comprising lauric acid, or a lauric acid derivative, are utilized independently, or in combination, to provide new and useful compositions for bacteriostatic action against susceptible pathogens. The lauric acid derivative includes one or more of 12-aminododecanoic acid, 12-amino-1-dodecanoic acid methyl ester, sucrose monolaurate, 12-(7-nitrobenzofurazan-4-ylamino) dodecanoic acid, 4-nitrophenyl dodecanoate, 1-lauroyl-rac-glycerol, 3-oxo-N-(2-oxocyclohexyl) dodecanamide, butyl laurate, benzyl laurate, isoamyl laurate, monolaurin, isopropyl laurate, pentyl laurate, and hexyl laurate. A preparation includes combining the active component with lecithin, and after an initial processing phase, coating with chitosan or a carrier. Final compositions may be or may contain particles, such as nanoparticles. Final compositions, or formulations containing said final compositions, may be utilized internally, causing one or more membrane changes (e.g., a membrane of an internal target pathogen, which may or may not be an antibiotic-resistant pathogen). At least some compositions inhibit growth of one or more Gram-positive bacterial species and one or more Gram-negative bacterial species.

traducir

NANOEMULSION WITH PORPHYRIN SHELL

Publication No.: US2022296731A1 22/09/2022

Applicant:

UNIV HEALTH NETWORK [CA]

CN_114222591_PA

Absstract of: US2022296731A1

There is described herein a nanoparticle comprising an outer shell comprising a porphyrin salt, an expanded porphyrin salt or an analog of porphyrin salt, around an inner oil core.

traducir

ROOM TEMPERATURE STABLE, SINGLE SHOT mRNA VACCINE FOR COVID-19

Publication No.: US2022296728A1 22/09/2022

Applicant:

CASTOR TREVOR PERCIVAL [US]

Absstract of: US2022296728A1

This disclosed technology relates to a new mRNA COVID-19 vaccine that is stable at room temperature, requires only one injection, and is less prone to patient hypersensitivity reactions. The vaccine is practical to deploy globally during vaccination campaigns for current and future coronavirus pandemics and other infectious diseases. The disclosed technology is a method and system for producing the vaccine, and also a double-encapsulated mRNA vaccine product. The method uses double nanoencapsulation of an mRNA vaccine, first in phospholipid nanosomes and then in biodegradable polymer nanospheres. The method may be carried out as a continuous flow, integral, or two-stage processes. The method and system use supercritical fluid technology for nanoencapsulating mRNA in a solvent free process that minimizes loss of potency and preserves antigenicity of the nanoencapsulated mRNA and eliminates residual organic solvents in the final product. The double-encapsulated mRNA vaccine product is stable at room temperature and can be administered in a single shot to humans.

traducir

ORAL DELIVERY SYSTEM

Publication No.: US2022296683A1 22/09/2022

Applicant:

UNIV DUBLIN [IE]

WO_2021053246_A1

Absstract of: US2022296683A1

The invention provides a method of preparing a silica-protein sub-micron particle, the method comprising contacting, in an aqueous medium having a pH in the range of about 7.5 to 10 and having an ionic strength in the range of about 1.2 to 60 mM, (i) protein sub-micron particle cores comprising 0.2 to 3 μmoles, per mg of the protein sub-micron particle cores, of a basic compound of formula (I) or an ester and/or amide thereof wherein n is an integer selected from 1 to 10, and p is an integer selected from 1 to 3, with (ii) orthosilicic acid or an ester thereof, in an amount equivalent to 5 to 60% (w/w) orthosilicic acid per mg of the protein sub-micron particle cores, to form the silica-protein sub-micron particle. The invention also provides a method of making a GLP-1 receptor agonist sub-micron particle core, by a. contacting a peptide in an aqueous medium at a pH of about 5.0-8.0 and comprising about 0.3-1.3 mM peptide, wherein the peptide is a GLP-1 receptor agonist, with the above-mentioned basic compound of formula (I) or an ester and/or amide thereof: wherein n is an integer selected from 1 to 10, and p is an integer selected from 1 to 3; in a molar ratio between the peptide and the basic compound of from 1:about 20 to 1:about 90 to form a step a. reaction mixture having a pH of about 7.5 to 10.0; optionally about 9.5; b. contacting the step a. reaction mixture with zinc to form a step b. reaction mixture, wherein the ratio of peptide:basic compound:zinc in the step b

traducir

TARGETED NANO-PHOTOMEDICINES FOR PHOTODYNAMIC THERAPY OF CANCER

Publication No.: US2022296714A1 22/09/2022

Applicant:

UNIV ERASMUS MED CT ROTTERDAM [NL]
AMRITA VISHWA VIDYAPEETHAM UNIV [IN]

US_2012184495_A1

Absstract of: US2022296714A1

The present invention relates to a photosensitizer-containing nanoparticle, comprising a photosensitizer covalently bonded throughout at least a part of said nanoparticle to the nanoparticle matrix material and incorporated therein in a quasi-aggregated state. The present invention further relates to methods for producing the invention nanoparticles, and to methods of killing cancer cells by PDT treatment using the said nanoparticles.

traducir

MEMBRANE FOR STICKING TO LIVING ORGANISM, AND METHOD FOR PRODUCING SAME

Publication No.: US2022296721A1 22/09/2022

Applicant:

PANASONIC IP MAN CO LTD [JP]

KR_20190083980_A

Absstract of: US2022296721A1

A cellulose membrane according to an embodiment of the present disclosure is a self-supporting cellulose membrane having a thickness of between 20 nm and 1300 nm, inclusive, composed of regenerated cellulose having a weight average molecular weight of 150,000 or more.

traducir

SYSTEMS AND METHODS FOR HIGH-THROUGHPUT SCREENING AND ANALYSIS OF DRUG DELIVERY SYSTEMS IN VITRO

Nº publicación: US2022299494A1 22/09/2022

Applicant:

TUFTS COLLEGE [US]

WO_2021041980_A1

Absstract of: US2022299494A1

The present disclosure provides a method for screening drug delivery vehicles for use in delivering cargo via oral delivery. The method includes introducing a drug delivery vehicle comprising an imaging agent into a lumen of an artificial intestine system composed of a scaffold matrix material. The scaffold matrix material includes an interconnected network of pores, intestinal epithelial cells positioned on an inner surface of the lumen, and human-based cells positioned within the pores and surrounding the intestinal epithelial cells. The method includes maintaining the artificial intestine system in physiologically relevant conditions for a predetermined length of time, and detecting a color change induced by the imaging agent within at least a portion of the human-based cells.

traducir

previousPage Page2/6 nextPage results/page

punteroimgGo back